0001127602-13-003944.txt : 20130204 0001127602-13-003944.hdr.sgml : 20130204 20130204165659 ACCESSION NUMBER: 0001127602-13-003944 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130131 FILED AS OF DATE: 20130204 DATE AS OF CHANGE: 20130204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tessmer James F CENTRAL INDEX KEY: 0001434095 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 13570754 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2013-01-31 0001062822 LEXICON PHARMACEUTICALS, INC./DE LXRX 0001434095 Tessmer James F 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381 1 VP, Finance & Accounting Common Stock 2013-01-31 4 M 0 13200 A 41870 D Common Stock 2013-01-31 4 F 0 4310 2.11 D 37560 D Restricted Stock Units (Phantom Stock) 2013-01-31 4 M 0 13200 D Common Stock 13200 0 D Each restricted stock unit represents a contingent right to receive one share of common stock. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Restricted stock units vest with respect to 100% of the shares subject to the restricted stock unit upon the dosing of the first patient in a pivotal human clinical trial in any country, the results of which could be used to establish safety and efficacy of a pharmaceutical product discovered or developed by the Company (whether or not licensed by the Company to a third party) as a basis for a New Drug Application with the U.S. Food and Drug Administration or that would otherwise satisfy the requirements of 21 CFR 321.21(c) or its foreign equivalent. /s/ James F. Tessmer 2013-02-01